Replimune Group (NASDAQ:REPL) Sets New 12-Month High – Still a Buy?

Replimune Group, Inc. (NASDAQ:REPL) hit a new 52-week high on Tuesday. The stock traded as high as $21.26 and last traded at $20.2010, with a volume of 705,865 shares traded. The stock had previously closed at $19.49.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Finally, Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.

Replimune Group Price Performance

The stock has a market capitalization of $1.93 billion, a PE ratio of -7.18 and a beta of 0.93. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The stock’s 50-day moving average is $13.89 and its 200 day moving average is $9.53.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. As a group, equities analysts predict that Replimune Group, Inc. will post -2.40 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In related news, CEO Sushil Patel sold 39,341 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the transaction, the chief executive officer directly owned 708,151 shares in the company, valued at approximately $9,184,718.47. This represents a 5.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Hill sold 9,256 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the transaction, the chief financial officer directly owned 215,852 shares of the company’s stock, valued at approximately $3,082,366.56. This trade represents a 4.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 100,624 shares of company stock valued at $1,446,864 in the last quarter. 5.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Replimune Group during the second quarter worth about $99,171,000. Montanova Capital LLC grew its holdings in Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after buying an additional 168,000 shares in the last quarter. Opaleye Management Inc. bought a new position in Replimune Group in the 2nd quarter valued at $15,332,000. Dimensional Fund Advisors LP raised its holdings in shares of Replimune Group by 1.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock valued at $8,719,000 after acquiring an additional 20,742 shares in the last quarter. Finally, EcoR1 Capital LLC purchased a new stake in Replimune Group in the first quarter valued at approximately $7,650,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.